ABSTRACT

Introduction: The most widely used pharmacological treatment for Parkinson’s disease is levodopa, the precursor for dopamine formation in the brain. Over time, the effectiveness of levodopa declines, and patients experience motor fluctuations, or OFF periods. A levodopa formulation administered via a capsule-based oral inhaler provides a new delivery mechanism for levodopa that provides rapid relief of OFF periods.

Areas covered: CVT-301 is a dry powder formulation designed to supply levodopa to the systemic circulation via pulmonary absorption. The technology, pharmacokinetics, efficacy, and safety data of this formulation are presented.

Expert opinion: Oral inhalation is a novel method of administration for levodopa that bypasses the gastrointestinal tract, allowing levodopa to enter the systemic circulation rapidly and more reliably than oral medications. Gastrointestinal dysfunction, a common feature of Parkinson’s disease, can lead to impaired absorption of oral medications. Pulmonary delivery rapidly elevates levodopa plasma concentrations to provide relief of OFF periods for patients receiving oral levodopa.

摘要

简介: 帕金森病最广泛使用的药物治疗是左旋多巴，它是大脑中多巴胺形成的前体。随着时间的推移，左旋多巴的有效性下降，患者会出现运动波动或关闭期。通过基于胶囊的口服吸入器给药的左旋多巴制剂为左旋多巴提供了一种新的递送机制，可快速缓解停药期。

涵盖领域： CVT-301 是一种干粉制剂，旨在通过肺部吸收向体循环提供左旋多巴。介绍了该制剂的技术、药代动力学、功效和安全性数据。

专家意见：口服吸入是左旋多巴绕过胃肠道的一种新型给药方法，使左旋多巴比口服药物更快速、更可靠地进入体循环。胃肠功能障碍是帕金森病的一个常见特征，可导致口服药物吸收受损。肺部给药可迅速提高左旋多巴的血浆浓度，以缓解接受口服左旋多巴的患者的停药期。